Lapatinib

Summary

Lapatinib (CHEMBL554) is an approved small-molecule antineoplastic agent (ATC L01EH01) targeting EGFR and ERBB2; indicated across 36 conditions including neoplasm and breast carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01EH01
• Targets: 2 (EGFR, ERBB2)
• Indications: 36 conditions
• Clinical trials: 262
• Chemistry: 581.1 Da · C29H26ClFN4O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL554
Name	Lapatinib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	208908
ChEBI	CHEBI:49603
ATC	L01EH01
Molecular formula	C29H26ClFN4O4S
Molecular weight	581.1
InChIKey	BCFGMOOMADDAQU-UHFFFAOYSA-N

SMILES: CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl

IUPAC name: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine

Pharmacological roles (ChEBI): antineoplastic agent, tyrosine kinase inhibitor.

Also known as: GSK-572016, GW-2016, GW-572016, GW-572016X, GW572016, Lapatinib, Tyverb, TYKERB, TYVERB, GW572016F, LAPATINIB DITOSYLATE MONOHYDRATE, FMM

Parent form; salt/anhydrous children: CHEMBL1076241, CHEMBL1201179, CHEMBL1201183, CHEMBL3526325

Patent coverage: 17,872 distinct patent families (69,326 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 68,757 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
EGFR	epidermal growth factor receptor	Inhibition	8	17.5%	P00533
ERBB2	erb-b2 receptor tyrosine kinase 2	Inhibition	7.89	17.7%	P04626

Broader ChEMBL bioactivity targets: 27 (assay-derived). Sample: Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma, Receptor tyrosine-protein kinase erbB-2, Tyrosine-protein kinase ABL1, Platelet-derived growth factor receptor beta, Insulin receptor, Epidermal growth factor receptor, Proto-oncogene tyrosine-protein kinase receptor Ret, Menin/Histone-lysine N-methyltransferase MLL, Epidermal growth factor receptor and ErbB2 (HER1 and HER2), Aurora kinase B.

Bioactivity

ChEMBL activities: 243 potent at pChembl ≥ 5 of 263 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
EGFR	10.22	IC50	0.06	nM	CHEMBL_ACT_22408240
EGFR	9.7	IC50	0.2	nM	CHEMBL_ACT_22408232
EGFR	9.05	Kd	0.9	nM	CHEMBL_ACT_25790342
EGFR	9.04	Kd	0.92	nM	CHEMBL_ACT_25790322
EGFR	9.04	Kd	0.92	nM	CHEMBL_ACT_2898753
EGFR	9.04	Kd	0.92	nM	CHEMBL_ACT_7580142
EGFR	8.92	Kd	1.2	nM	CHEMBL_ACT_25790328
EGFR	8.92	Kd	1.2	nM	CHEMBL_ACT_25790343
EGFR	8.92	Kd	1.2	nM	CHEMBL_ACT_2904727
EGFR	8.92	Kd	1.2	nM	CHEMBL_ACT_7582068
ERBB2	8.8	Ki	1.58	nM	CHEMBL_ACT_9614678
ERBB2	8.8	Ki	1.58	nM	CHEMBL_ACT_9618393
EGFR	8.74	IC50	1.8	nM	CHEMBL_ACT_19187589
EGFR	8.68	Kd	2.1	nM	CHEMBL_ACT_25790323
EGFR	8.68	Kd	2.1	nM	CHEMBL_ACT_25790344
EGFR	8.68	Kd	2.1	nM	CHEMBL_ACT_2898791
EGFR	8.68	Kd	2.1	nM	CHEMBL_ACT_7580143
EGFR	8.66	Kd	2.2	nM	CHEMBL_ACT_25790324
EGFR	8.66	Kd	2.2	nM	CHEMBL_ACT_25790345
EGFR	8.66	Kd	2.2	nM	CHEMBL_ACT_2898829
EGFR	8.66	Kd	2.2	nM	CHEMBL_ACT_7580144
EGFR	8.62	Kd	2.4	nM	CHEMBL_ACT_25790320
EGFR	8.62	Kd	2.4	nM	CHEMBL_ACT_25790346
EGFR	8.62	Kd	2.4	nM	CHEMBL_ACT_2898677
EGFR	8.62	Kd	2.4	nM	CHEMBL_ACT_7580140
ERBB2	8.57	IC50	2.7	nM	CHEMBL_ACT_15130273
EGFR	8.55	Kd	2.8	nM	CHEMBL_ACT_20689378
ERBB2	8.55	IC50	2.8	nM	CHEMBL_ACT_22408419
EGFR	8.55	Kd	2.8	nM	CHEMBL_ACT_25790327
EGFR	8.55	Kd	2.8	nM	CHEMBL_ACT_25790347

Target pathways

Aggregated over 2 target gene(s): EGFR, ERBB2.

Top Reactome pathways

53 total, by targets touching each:

Pathway	Targets	Genes
Signaling by ERBB2	2	EGFR, ERBB2
SHC1 events in ERBB2 signaling	2	EGFR, ERBB2
PLCG1 events in ERBB2 signaling	2	EGFR, ERBB2
PIP3 activates AKT signaling	2	EGFR, ERBB2
GRB2 events in ERBB2 signaling	2	EGFR, ERBB2
PI3K events in ERBB2 signaling	2	EGFR, ERBB2
Constitutive Signaling by Aberrant PI3K in Cancer	2	EGFR, ERBB2
RAF/MAP kinase cascade	2	EGFR, ERBB2
ERBB2 Regulates Cell Motility	2	EGFR, ERBB2
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	2	EGFR, ERBB2
ERBB2 Activates PTK6 Signaling	2	EGFR, ERBB2
Downregulation of ERBB2 signaling	2	EGFR, ERBB2
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	2	EGFR, ERBB2
Signaling by ERBB2 KD Mutants	2	EGFR, ERBB2
Signaling by ERBB2 ECD mutants	2	EGFR, ERBB2
Signaling by ERBB2 TMD/JMD mutants	2	EGFR, ERBB2
Developmental Lineage of Mammary Gland Myoepithelial Cells	2	EGFR, ERBB2
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	1	EGFR
Signaling by ERBB4	1	EGFR
GRB7 events in ERBB2 signaling	1	ERBB2
Downregulation of ERBB2:ERBB3 signaling	1	ERBB2
Signaling by EGFR	1	EGFR
GRB2 events in EGFR signaling	1	EGFR
GAB1 signalosome	1	EGFR
SHC1 events in EGFR signaling	1	EGFR
EGFR downregulation	1	EGFR
EGFR interacts with phospholipase C-gamma	1	EGFR
EGFR Transactivation by Gastrin	1	EGFR
Sema4D induced cell migration and growth-cone collapse	1	ERBB2
Signal transduction by L1	1	EGFR

Dominant GO biological processes

GO term	Targets
signal transduction	2
cell surface receptor signaling pathway	2
epidermal growth factor receptor signaling pathway	2
neuron differentiation	2
positive regulation of cell growth	2
ERBB2-EGFR signaling pathway	2
negative regulation of apoptotic process	2
positive regulation of MAPK cascade	2
phosphatidylinositol 3-kinase/protein kinase B signal transduction	2
positive regulation of epithelial cell proliferation	2
cellular response to epidermal growth factor stimulus	2
protein phosphorylation	2
cell surface receptor protein tyrosine kinase signaling pathway	2
cell population proliferation	2
regulation of cell population proliferation	2

Indications & clinical

Indications

36 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
breast carcinoma	3	MONDO:0004989	EFO:0000305
breast neoplasm	3	MONDO:0021100	EFO:0003869
brain disorder	3	MONDO:0005560	EFO:0005774
soft tissue sarcoma	3	MONDO:0018078	EFO:1001968
head and neck cancer	3	MONDO:0005627	EFO:0006859
head and neck neoplasm	3	MONDO:0005586	EFO:0005950
HER2 positive breast carcinoma	3	MONDO:0006244	EFO:1000294
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
melanoma	2	MONDO:0005105	EFO:0000756
squamous cell carcinoma	2	MONDO:0005096	EFO:0000707
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
adenocarcinoma	2	MONDO:0004970	EFO:0000228
colorectal adenocarcinoma	2	MONDO:0005008	EFO:0000365
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
pituitary gland adenoma	2	MONDO:0006373	EFO:1000478
esophageal squamous cell carcinoma	2	MONDO:0005580	EFO:0005922
breast ductal adenocarcinoma	2	MONDO:0005590	EFO:0006318
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
brain cancer	2	MONDO:0001657	MONDO:0001657
peritoneal neoplasm	2	MONDO:0006901	MONDO:0002087
ovarian cancer	2	MONDO:0008170	MONDO:0008170
bile duct carcinoma	2	MONDO:0005496	EFO:0005540
paraganglioma	2	MONDO:0000448	EFO:1000453
gallbladder neoplasm	2	MONDO:0021253	MONDO:0005411
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
chronic kidney disease	1	MONDO:0005300	EFO:0003884
renal cell carcinoma	1	MONDO:0005086	EFO:0000681
thyroid gland carcinoma	1	MONDO:0015075	EFO:0002892
endometrium neoplasm	1	MONDO:0021251	MONDO:0011962

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 262.

Phase distribution

Phase	Trials
PHASE2	130
PHASE1	62
PHASE3	32
PHASE1/PHASE2	19
Not specified	9
EARLY_PHASE1	5
PHASE2/PHASE3	4
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01328054	PHASE4	COMPLETED	A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
NCT06313983	PHASE3	RECRUITING	A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
NCT00073528	PHASE3	COMPLETED	Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
NCT00075270	PHASE3	COMPLETED	Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
NCT00078572	PHASE3	COMPLETED	Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer
NCT00272987	PHASE3	TERMINATED	ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
NCT00281658	PHASE3	COMPLETED	Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2
NCT00320385	PHASE3	COMPLETED	Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
NCT00374322	PHASE3	COMPLETED	Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
NCT00390455	PHASE3	COMPLETED	Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
NCT00424255	PHASE3	COMPLETED	Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
NCT00450203	PHASE2/PHASE3	UNKNOWN	Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
NCT00486668	PHASE3	UNKNOWN	A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
NCT00486954	PHASE3	COMPLETED	Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
NCT00490139	PHASE3	COMPLETED	ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
NCT00508274	PHASE3	TERMINATED	Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
NCT00553358	PHASE3	COMPLETED	Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
NCT00667251	PHASE3	COMPLETED	Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
NCT00680901	PHASE3	COMPLETED	LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
NCT00688194	PHASE3	UNKNOWN	Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
NCT00770809	PHASE3	COMPLETED	Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00820222	PHASE3	COMPLETED	Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
NCT00829166	PHASE3	COMPLETED	A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT00949455	PHASE2/PHASE3	UNKNOWN	A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium
NCT00968968	PHASE3	TERMINATED	Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
NCT01104571	PHASE3	UNKNOWN	Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer
NCT01160211	PHASE3	COMPLETED	A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
NCT01526369	PHASE3	COMPLETED	A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer
NCT01619111	PHASE3	COMPLETED	DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
NCT01808573	PHASE3	COMPLETED	A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
NCT02394496	PHASE3	UNKNOWN	Overcoming Endocrine Resistance in Metastatic Breast Cancer
NCT03084939	PHASE3	COMPLETED	Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
NCT03085368	PHASE2/PHASE3	UNKNOWN	A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
NCT03500380	PHASE2/PHASE3	UNKNOWN	A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
NCT03523585	PHASE3	COMPLETED	DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
NCT03784014	PHASE3	COMPLETED	Molecular Profiling of Advanced Soft-tissue Sarcomas
NCT04185649	PHASE3	UNKNOWN	The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT00999804	PHASE2	ACTIVE_NOT_RECRUITING	Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
NCT01273610	PHASE2	ACTIVE_NOT_RECRUITING	Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
NCT00044343	PHASE2	COMPLETED	GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 14 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

171 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, ERBB2
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, ERBB2
DACOMITINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, ERBB2
GEFITINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, ERBB2
LAZERTINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, ERBB2
MOBOCERTINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, ERBB2
SELUMETINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, ERBB2
ACALABRUTINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
AFATINIB DIMALEATE	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
BITHIONOL	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
BOSUTINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
BRIGATINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
CABOZANTINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
COLISTIN	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
DASATINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
EBASTINE	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
ECONAZOLE	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
ERLOTINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
IBRUTINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
IMATINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
MICONAZOLE	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
MITOXANTRONE	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
NERATINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
OSIMERTINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
PONATINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
SORAFENIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
TAMOXIFEN	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
TRIBROMSALAN	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
TUCATINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
VANDETANIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
ZANUBRUTINIB	ChEMBL	Phase 4 (approved)	EGFR, ERBB2
ALISERTIB	ChEMBL	Phase 3	EGFR, ERBB2
ALVOCIDIB	ChEMBL	Phase 3	EGFR, ERBB2
CANDESARTAN	ChEMBL	Phase 3	EGFR, ERBB2
CANERTINIB	ChEMBL	Phase 3	EGFR, ERBB2
CEDIRANIB	ChEMBL	Phase 3	EGFR, ERBB2
ENCLOMIPHENE	ChEMBL	Phase 3	EGFR, ERBB2
MASITINIB	ChEMBL	Phase 3	EGFR, ERBB2
POZIOTINIB	ChEMBL	Phase 3	EGFR, ERBB2
PYROTINIB	ChEMBL	Phase 3	EGFR, ERBB2
REMIBRUTINIB	ChEMBL	Phase 3	EGFR, ERBB2
ZONGERTINIB	ChEMBL	Phase 3	EGFR, ERBB2
AEE-788	ChEMBL	Phase 2	EGFR, ERBB2
ALLITINIB	ChEMBL	Phase 2	EGFR, ERBB2
ATUZABRUTINIB	ChEMBL	Phase 2	EGFR, ERBB2
CENISERTIB	ChEMBL	Phase 2	EGFR, ERBB2
CLOSANTEL	ChEMBL	Phase 2	EGFR, ERBB2
CP-724714	ChEMBL	Phase 2	EGFR, ERBB2
DEFOSBARASERTIB	ChEMBL	Phase 2	EGFR, ERBB2
ELLAGIC ACID	ChEMBL	Phase 2	EGFR, ERBB2
FALNIDAMOL	ChEMBL	Phase 2	EGFR, ERBB2
FORETINIB	ChEMBL	Phase 2	EGFR, ERBB2
ILORASERTIB	ChEMBL	Phase 2	EGFR, ERBB2
IODOQUINOL	ChEMBL	Phase 2	EGFR, ERBB2
PELITINIB	ChEMBL	Phase 2	EGFR, ERBB2